Immune checkpoint inhibitor induced colitis and arthritis: A case report
Rong-Xin Xie,Yu-Bao Xue,Xin-Yu Ci,Mei-Juan Zhang
DOI: https://doi.org/10.1097/md.0000000000036334
IF: 1.6
2024-02-23
Medicine
Abstract:The emergence of immune checkpoint inhibitors marks a new era in cancer therapy, and their continuous evolution has brought major breakthroughs in cancer treatment. [ 1 ] As the preferred treatment for advanced cancer, immune checkpoint inhibitors have achieved remarkable success in melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma and other tumors. [ 2 ] Programmed cell death protein-1 (PD-1) is a cell surface receptor present on T cells. As an immune checkpoint, PD-1 inhibits the transcription of related genes by specifically binding to its ligand PD-L1, thereby preventing the proliferation of T cells and ultimately leading to the loss of immune function. [ 3 ] As a result, some tumors can express PD-L1 at high levels, with the aim of weakening the T cell immune response to them. Camrelizumab (AiRuiKa) is a humanized high-affinity IgG 4-κ anti-PD-1 monoclonal antibody that acts by binding to and blocking the binding of PD-1 to its ligand, PD-L1. [ 4 ] However, this may lead to excessive activation of T cells, triggering T cell imbalance, which in turn leads to adverse immune responses, including immune-related reactive cutaneous capillary endothelial cell proliferation (RCCEP), colitis, arthritis, hepatitis, etc.
medicine, general & internal